SC3613 / Korea Kolmar, Dong-A - LARVOL DELTA

SC3613 (IN-207387), a mutant-selective EGFR degrader, exhibits potent anti-tumor activity and improved safety profile in EGFR TKI-resistant NSCLC (AACR 2026) - "However, patients with L858R-driven tumors exhibit a poorer prognosis and shorter progression-free survival even with third-generation EGFR TKIs, such as osimertinib, compared with those harboring exon 19 deletions, underscoring a substantial unmet clinical need in this molecular subgroup. Collectively, these findings identify SC3613 as a potent, highly mutant-selective, and orally active EGFR degrader with robust anti-tumor efficacy and improved safety. SC3613 represents a promising next-generation therapeutic candidate for NSCLC patients harboring activating and resistance mutations such as L858R, T790M, and C797S."

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor